Research indicates that the impact of mTOR inhibitors on CSC may rely on the genetic background and rewiring of cancer stemness pathways; however, the connection between mTOR inhibitors and CSC is complicated, and their further relationship to RiBi [97] or tumor cell resistance [98] has not yet been reported. The gene discussed is MTOR; the disease is neoplasm.